The early FDA approval doesn’t…
The early FDA approval doesn’t change Pfizer and Arvinas’ plan [...]
Four years after gaining FDA…
Four years after gaining FDA approval for Auvelity to treat [...]
Shortly after laying out $75…
Shortly after laying out $75 million upfront for Corstasis Therapeutics [...]
The company looks to achieve an…
The company looks to achieve an “amicable resolution as soon [...]
A surprise interim trial miss in…
A surprise interim trial miss in ivonescimab’s closely watched Harmoni-3 [...]
As Eli Lilly gets off to the races…
As Eli Lilly gets off to the races with the [...]
Bristol Myers Squibb’s growth…
Bristol Myers Squibb’s growth portfolio is offsetting declines in older [...]
While Merck’s PAH treatment…
While Merck’s PAH treatment Winrevair continued its upward trajectory, another [...]
As AstraZeneca braces for the…
As AstraZeneca braces for the impact of the U.S. “most [...]
While Teva Pharmaceutical’s…
While Teva Pharmaceutical’s multiyear growth streak under CEO Richard Francis [...]